ReGenTree, a joint venture between GtreeBNT and RegeneRx Biopharmaceuticals, announced that the company presented results of a comparison study of RGN-259 and marketed products for dry eye syndrome in a dry eye mouse model at ARVO (The Association for Research in Vision and Ophthalmology) meeting in Honolulu, Hawaii.
The study was conducted by Jaewook Yang, MD, at the T2B Infrastructure Center for Ocular Disease, InJe University Busan Paik Hospital in Korea. Gabriel Sosne, MD, at Wayne State University School of Medicine and Hynda Kleinman, PhD, at The George Washington University School of Medicine were among the authors of the study.
The study found that RGN-259 treatment promoted recovery of mucins and goblet cells, improved corneal integrity, increased tears, and reduced inflammation in a dry eye mouse model. Such improvements with RGN-259 treatment were comparable to or better than that seen with approved prescription treatments such as cyclosporine A (Restasis), lifitegrast (Xiidra), and diquafosol (Diquas), which are marketed in the USA or Japan. For detailed information about the results, please refer to abstract number 3807-C0034 at 2018 ARVO.
ReGenTree’s phase 3 clinical program includes two completed studies in dry eye syndrome that demonstrated positive clinical results for signs and symptoms of dry eye within the RGN-259 group compared to placebo and an ongoing study in patients with chronic neurotrophic keratopathy, an orphan indication. RGN-259 has also demonstrated a strong safety profile with fewer side effects compared to approved products currently on the market.